Discover
AKBA
Akebia Therapeutics, Inc.
1.21
25 x 1.15
2 x 1.48
bid
ask
+
0.07
6.14%
14 @ 05:33 AM
1.22 +0.01 (0.83%)
| Ytd | -24.84% | |
| 1y | -66.11% |
1.15
day range
1.25
0.82
52 week range
4.08
| Open | 1.15 | Prev Close | 1.14 | Low | 1.15 | High | 1.25 | Mkt Cap | 324.59M |
| Vol | 6.04M | Avg Vol | 4.72M | EPS | -0.08 | P/E | N/A | Forward P/E | -7.15 |
| Beta | 0.73 | Short Ratio | 4.71 | Inst. Own | 27.33% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 1.13 | 200-d Avg | 1.63 | 1yr Est | 5.50 |
AKBA News
benzinga.com
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ:AKBA) wit
benzinga.com
Akebia Therapeutics, U.S. Renal Care Announce U.S. Renal Care Kidney Research Proposed To Halt Vafse
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better th
globenewswire.com
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statis
Vafseo® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due
benzinga.com
Akebia Therapeutics Granted New Patent And Listed In Orange Book; Notified Of Eligibility To Extend
Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the